natgillin/translations-raw huggingface dataset:
N = total number of patients treated.
Razmerje tveganja (95-odstotni IZ) n = celotno število zdravljenih bolnikov IZ = interval zaupanja
Each vial contains 4 mg topotecan (as hydrochloride) in 4 ml concentrate.
Vsaka viala vsebuje 4 mg topotekana (v obliki topotekanijevega klorida) v 4 ml koncentrata.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS Vial Label
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Prior to administration of the first course of topotecan, patients must have a baseline neutrophil count of ≥ 1.5 x 109/l, a platelet count of ≥ 100 x 109/l and a haemoglobin level of ≥ 9 g/dl (after transfusion if necessary).
Pred prvim ciklusom zdravljenja s topotekanom morajo imeti bolniki izhodiščno število nevtrofilcev ≥ 1,5 x 109/l, število trombocitov ≥ 100 x 109/l ter raven hemoglobina ≥ 9 g/dl (po prejemu transfuzije, če je ta potrebna).
Feeling generally weak and tired, which can be symptoms of a decrease in the number of red blood cells (anaemia).
Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov) - Občutek splošne oslabelosti in utrujenosti, ki sta lahko znaka zmanjšanega števila rdečih krvničk (anemija).
Cisplatin 50 mg/m2 on day 1 + Topotecan 0.75 mg/m2 on days 1-3, every 21 days
1. dan vsakih 21 dni cisplatin 50 mg/m2 na 1. dan +
Your dose of Topotecan Teva will depend on: the disease being treated your body surface area (m2) the results of blood tests carried out before and during treatment how well you tolerate treatment.
Vaš odmerek zdravila Topotekan Teva bo odvisen od: - bolezni, zaradi katere se zdravite, - vaše telesne površine (m2),
How Topotecan Teva is prepared
Kako se zdravilo Topotekan Teva pripravi
Topotecan Teva 1 mg/1 ml concentrate for solution for infusion Topotecan Teva 4 mg/4 ml concentrate for solution for infusion
Topotekan Teva 1 mg/1 ml koncentrat za raztopino za infundiranje Topotekan Teva 4 mg/4 ml koncentrat za raztopino za infundiranje
Very common Nausea, vomiting and diarrhoea (all of which may be severe), constipation, abdominal pain2, mucositis
Bolezni prebavil zelo pogosti navzea, bruhanje in driska (vse lahko v hudi obliki), zaprtje, bolečine v trebuhu2, vnetje ustne sluznice pogostnost neznana gastrointestinalna perforacija
Frequently reported non-haematological effects were gastrointestinal, such as nausea (52 %), vomiting (32 %), diarrhoea (18 %), constipation (9 %) and mucositis (14 %).
bruhanje (32 %), driska (18 %), zaprtje (9 %) in vnetje ustne sluznice (14 %).
In those patients (n = 102) with recurrence after 180 days, median survival in the topotecan plus cisplatin arm was 9.9 months (95 % CI: 7, 12.6) versus 6.3 months (95 % CI: 4.9, 9.5) for the cisplatin arm with a hazard ratio of 0.75 (0.49, 1.16).
Pri bolnicah (n = 102) s ponovitvijo po 180 dneh je bila mediana preživetja v skupini, ki je prejemala topotekan in cisplatin, 9,9 meseca (95-odstotni IZ: 7, 12,6) v skupini, ki je prejemala cisplatin, pa 6,3 meseca (95-odstotni IZ: 4,9, 9,5), razmerje ogroženosti 0,75 (0,49, 1,16).
ovarian cancer or small cell lung cancer that has come back after chemotherapy advanced cervical cancer if surgery or radiotherapy treatment is not possible.
- napredovalega raka materničnega vratu, če zdravljenje z operacijo ali obsevanjem ni možno.
Tell a doctor if any of these becomes troublesome.
→ Zdravniku morate povedati, če menite, da kaj od tega velja za vas.
Women of childbearing potential / Contraception in males and females Topotecan has been shown to cause embryo-foetal lethality and malformations in preclinical studies (see section 5.3).
Predklinične raziskave so pokazale, da topotekan povzroča smrt in deformacije zarodka oziroma ploda (glejte poglavje 5.3).
Colourless, type I glass vial with bromobutyl rubber stopper, aluminium seal and polypropylene snapcap containing 1 ml or 4 ml of concentrate.
Brezbarvana viala iz stekla tipa I z zamaškom iz brombutilne gume, aluminijasto zaporko in polipropilenskim natičnim pokrovom.
The use of Topotecan Teva is not recommended in patients with severe renal impairment; if you have liver problems.
Uporaba zdravila Topotekan Teva pri bolnikih s hudo okvaro ledvic se ne priporoča.
Patients with renal impairment
Posebne skupine bolnikov Bolniki z okvaro ledvic
The incidence of severe (Grade 3 or 4) nausea, vomiting, diarrhoea and mucositis was 4, 3, 2 and 1 % respectively.
Hude oblike (3. ali 4. stopnje) motenj so ugotavljali z naslednjimi pogostnostmi: navzea 4 %, bruhanje 3 %, driska 2 %, vnetje ustne sluznice 1 %.
Relapsed ovarian cancer
Rak jajčnikov in drobnocelični pljučni rak
However there are insufficient data available to make a dose recommendation for this patient group (see section 4.2).
Pri tem so opažali zmanjšan očistek topotekana, vendar ni na voljo dovolj podatkov, da bi lahko oblikovali priporočila za odmerjanje za to skupino bolnikov (glejte poglavje 4.2).
How to store Topotecan Teva
Kako dajati zdravilo Topotekan Teva
Topotecan Teva 1 mg/1 ml concentrate for solution for infusion 1 ml of concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride).
Topotekan Teva 1 mg/1 ml koncentrat za raztopino za infundiranje 1 ml koncentrata za raztopino za infundiranje vsebuje 1 mg topotekana (v obliki topotekanijevega klorida).
if you are allergic to topotecan or any of the other ingredients of this medicine (listed in section if you are breast-feeding; if your blood cells count is too low.
- če ste alergični na topotekan ali katero koli sestavino tega zdravila (navedeno v poglavju 6),
EXP Read the leaflet for the shelf life of the diluted product.
EXP Za rok uporabnosti pripravljenega zdravila preberite priložena navodila.
Topotecan Teva 4 mg/4 ml concentrate for solution for infusion 1 ml of concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride).
Topotekan Teva 4 mg/4 ml koncentrat za raztopino za infundiranje 1 ml koncentrata za raztopino za infundiranje vsebuje 1 mg topotekana (v obliki topotekanijevega klorida).
One Phase II study (Study 065) and one Phase III study (Study 396) were conducted to evaluate the efficacy of oral topotecan versus intravenous topotecan in patients who had relapsed ≥ 90 days after completion of one prior regimen of chemotherapy (see Table 1).
Za oceno učinkovitosti peroralnega topotekana v primerjavi z intravenskim topotekanom pri bolnikih, pri katerih je prišlo do ponovitve ≥ 90 dni po koncu ene predhodne sheme kemoterapije, so izvedli eno študijo faze II (Študija 065) in eno študijo faze III (Študija 396) (glejte preglednico 1).
Hydrochloric acid (E507) (for pH adjustment) Sodium hydroxide (E524) (for pH adjustment) Water for injections
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi vinska kislina (E334) klorovodikova kislina (E507) (za uravnavanje pH) natrijev hidroksid (E524) (za uravnavanje pH) voda za injekcije
Very common Febrile neutropenia, neutropenia (see “Gastrointestinal disorders”), thrombocytopenia, anaemia, leucopenia
Bolezni krvi in limfatičnega sistema zelo pogosti febrilna nevtropenija, nevtropenija (glejte "Bolezni prebavil"), trombocitopenija, anemija, levkopenija pogosti pancitopenija pogostnost neznana huda krvavitev (v povezavi s trombocitopenijo)
Oral and intravenous topotecan were associated with similar symptom palliation in patients with relapsed sensitive SCLC in patient self reports on an unblinded symptom scale assessment in each of these two studies.
Na podlagi neslepljene ocene lestvice simptomov po navedbi bolnikov samih sta peroralni in intravenski topotekan v obeh navedenih študijah pri bolnikih s ponovitvijo dovzetnega drobnoceličnega pljučnega raka dosegla podobno ublažitev simptomov.
Instructions for dilution
Navodilo za redčenje
The elimination of topotecan has only been partly investigated in man. A major route of clearance of topotecan was by hydrolysis of the lactone ring to form the ring-opened carboxylate.
Glavna pot razgradnje je hidroliza laktonskega obroča, s katero nastane karboksilat z odprtim obročem.
EU/1/09/552/001 - 1 vial EU/1/09/552/002 - 5 vials
EU/1/09/552/001 - 1 viala EU/1/09/552/002 - 5 vial
EU/1/09/552/003 - 1 vial EU/1/09/552/004 - 5 vials
EU/1/09/552/003 - 1 viala EU/1/09/552/004 - 5 vial
Median survivals for the two groups were 25.0 and 24.7 weeks respectively.
Mediana časa preživetja bolnikov v skupini, ki je prejemala topotekan, je bila 25,0 tedna, v skupini, ki je prejemala kombinacijo CAV pa 24,7 tedna.
One vial of 1 ml of concentrate contains 1 mg topotecan (as hydrochloride).
1 viala z 1 ml koncentrata vsebuje 1 mg topotekana (v obliki topotekanijevega klorida).
Decrease in the number of all blood cells (pancytopenia ) Allergic or hypersensitivity reactions (including rash).
- Alergijske ali preobčutljivostne reakcije (vključno z izpuščajem).
Topotecan Teva 1 mg/1 ml concentrate for solution for infusion topotecan
Topotekan Teva 1 mg/1 ml koncentrat za raztopino za infundiranje topotekan
Topotecan Teva 4 mg/4 ml concentrate for solution for infusion topotecan
Topotekan Teva 4 mg/4 ml koncentrat za raztopino za infundiranje topotekan
Ovarian and small cell lung cancer The usual dose is 1.5 mg per m2 of body surface area once daily for 5 days.
Običajni odmerek je 1,5 mg na m2 telesne površine enkrat na dan pet dni.
In a comparative study of topotecan and paclitaxel in patients previously treated for ovarian carcinoma with platinum based chemotherapy (n = 112 and 114, respectively), the response rate (95 % CI) was 20.5 % (13 %, 28 %) versus 14 % (8 %, 20 %) and median time to progression 19 weeks versus 15 weeks (hazard ratio 0.7 [0.6, 1.0]), for topotecan and paclitaxel,
Stopnja odzivnosti na zdravljenje (95-odstotni interval zaupanja) je znašala 20,5 % (13 %, 28 %) oziroma 14 % (8 %, 20 %), mediana časa do napredovanja pa 19 tednov za topotekan in 15 tednov za paklitaksel (razmerje ogroženosti 0,7 [0,6, 1,0]).
Relapsed SCLC
Log rank p-vrednost
One vial of 4 ml of concentrate for solution for infusion contains 4 mg topotecan (as hydrochloride).
Ena viala s 4 ml koncentrata za raztopino za infundiranje vsebuje 4 mg topotekana (v obliki topotekanijevega klorida).
EU/1/09/552/004- 5 vials
EU/1/09/552/004 - 5 vial
One vial of 4 ml of concentrate contains 4 mg topotecan (as hydrochloride).
1 viala s 4 ml koncentrata vsebuje 4 mg topotekana (v obliki topotekanijevega klorida).
Topotecan should not be re-administered unless the neutrophil count is ≥ 1 x 109/l, the platelet count is ≥ 100 x 109/l, and the haemoglobin level is ≥ 9 g/dl (after transfusion if necessary).
Pred naslednjo uporabo topotekana mora biti število nevtrofilcev ≥ 1 x 109/l, število trombocitov ≥ 100 x 109/l, vrednost hemoglobina pa ≥ 9 g/dl (po prejemu transfuzije, če je ta potrebna).
EU/1/09/552/002- 5 vials
EU/1/09/552/002 - 5 vial
There is little or no accumulation of topotecan with repeated daily dosing and there is no evidence of a change in the pharmacokinetics after multiple doses.
Prav tako ni znakov, da bi se farmakokinetika spremenila po večkratnem odmerjanju.
Itchy rash (or hives).
dispneja in/ali hipoksija).
1 ml of concentrate for solution for infusion contains 1 mg topotecan (as hydrochloride).
1 ml koncentrata za raztopino za infundiranje vsebuje 1 mg topotekana (v obliki topotekanijevega klorida).
Hazard ratio (95% CI)
Razmerje tveganja (95-odstotni IZ)
Very common Infection Common
Infekcijske in parazitske bolezni zelo pogosti okužba pogosti sepsa1
Topotecan should not be re-administered unless the neutrophil count is ≥ 1.5 x 109/l, the platelet count is ≥100 x 109/l, and the haemoglobin level is ≥ 9 g/dl (after transfusion if necessary).
Pred naslednjo uporabo topotekana mora biti število nevtrofilcev ≥ 1,5 x 109/l, število trombocitov ≥ 100 x 109/l in vrednost hemoglobina ≥ 9 g/dl (po prejemu transfuzije, če je ta potrebna).
Patients should be monitored for pulmonary symptoms indicative of ILD (e.g. cough, fever, dyspnoea and/or hypoxia), and topotecan should be discontinued if a new diagnosis of ILD is confirmed.
Pri bolnikih je potrebno spremljati morebitne pljučne znake IBP (npr. kašelj, vročina,
In another randomised Phase III study which compared intravenous (IV) topotecan to cyclophosphamide, doxorubicin and vincristine (CAV) in patients with relapsed, sensitive SCLC, the overall response rate was 24.3 % for topotecan compared to 18.3 % for the CAV group.
V drugi randomizirani študiji faze III so primerjali intravenski topotekan s ciklofosfamidom, doksorubicinom in vinkristinom (CAV).
Plasma clearance in patients with renal impairment (creatinine clearance 41-60 ml/min.)
Plazemski očistek pri bolnikih z ledvično okvaro (očistek kreatinina 41−60 ml/min) se je v primerjavi s kontrolno skupino zmanjšal na približno 67 %.
Package leaflet: Information for the user Topotecan Teva 4 mg/4 ml concentrate for solution for infusion topotecan
Navodilo za uporabo Topotekan Teva 4 mg/4 ml koncentrat za raztopino za infundiranje topotekan
You must tell your doctor immediately if you experience any of the following serious side effects.
Resni neželeni učinki: Če se pojavi kateri koli izmed navedenih resnih neželenih učinkov, morate nemudoma obvestiti zdravnika.
Respiratory, thoracic and mediastinal disorders
Bolezni jeter, žolčnika in žolčevodov pogosti hiperbilirubinemija
Difference in response rate (95% CI)
Razlika v deležu odziva (95-odstotni IZ) Mediani čas do napredovanja (tedni)
Package leaflet: Information for the user Topotecan Teva 1 mg/1 ml concentrate for solution for infusion topotecan
Navodilo za uporabo Topotekan Teva 1 mg/1 ml koncentrat za raztopino za infundiranje topotekan
The mean metabolite: parent AUC ratio was < 10% for both total topotecan and topotecan lactone.
Tako za celotni topotekan kot za topotekan lakton je srednje razmerje med vrednostima AUC presnovka in matične učinkovine manjše od 10 %.
Gastrointestinal perforation
Rezultati preskušanja GOG-0179
If you are being treated for cervical cancer, you may get side effects from the other medicine (cisplatin) that you will be given along with Topotecan Teva.
(cisplatina), ki ga boste prejeli skupaj z zdravilom Topotekan Teva.
Topotecan Teva is used to treat:
Samostojno zdravljenje s topotekanom je indicirano pri:
Very common Alopecia Common
Bolezni kože in podkožja zelo pogosti alopecija pogosti srbenje
Breast-feeding (see section 4.6).
(glejte poglavje 4.4).
Clear pale yellow liquid.
koncentrat za raztopino za infundiranje Bistra, bledo-rumena tekočina.
fever serious decline of your general condition local symptoms such as sore throat or burning sensation when urinating severe stomach pain, fever and possibly diarrhoea (rarely with blood) can be signs of bowel inflammation (neutropenic colitis).
− huda bolečina v želodcu, zvišana telesna temperatura in lahko tudi driska (redko krvava)
Detailed information on this medicine is available on the website of the European Medicines Agency
Podrobne informacije o tem zdravilu so na voljo na spletnih straneh Evropske agencije za zdravila http://www.ema.europa.eu/.
Date of first authorisation: 21 September 2009 Date of latest renewal: 8 May 2014
Datum prve odobritve: 21. september 2009 Datum zadnjega podaljšanja: 8. maj 2014
After opening: Use within 2 months.
Po odprtju: Porabite v 2 mesecih.
Open date:________
Datum odprtja:_______
After opening:
Po odprtju:
An occasional use of acetylsalicylic acid (no more than 1,000 mg in any 24 hour period) should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor.
Priložnostna uporaba acetilsalicilne kisline (ne več kot 1000 mg v kateremkoli 24-urnem obdobju) na splošno ne bi smela povzročati težav, vendar pa se morate o daljši uporabi v drugih okoliščinah posvetovati s svojim zdravnikom.
Some other medicines may influence the use of Clopidogrel BGR or vice versa.
Nekatera druga zdravila lahko vplivajo na jemanje zdravila Clopidogrel BGR in obratno.
Do not use this medicine after the expiry date which is stated on the packaging after EXP.
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na ovojnini poleg oznake "EXP".
Blister (OPA/Alu/PVC-Alu) 3 years.
Pretisni omot (OPA/Al/PVC-Al) 3 leta
If you experience prolonged bleeding when taking Clopidogrel BGR If you cut or injure yourself, it may take longer than usual for bleeding to stop.
Če doživite podaljšanje krvavitve v času jemanja zdravila Clopidogrel BGR Če se urežete ali poškodujete, lahko traja dlje kot običajno, da se krvavitev ustavi.
You should take Clopidogrel BGR for as long as your doctor continues to prescribe it.
Zdravilo Clopidogrel BGR morate jemati, dokler vam ga vaš zdravnik predpisuje.
Clopidogrel BGR with food and drink Clopidogrel BGR may be taken with or without food.
Zdravilo Clopidogrel BGR skupaj s hrano in pijačo Zdravilo Clopidogrel BGR lahko jemljete s hrano ali brez nje.
Patients with rare hereditary problems of galactose intolerance, the total lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.
Bolniki z redko dedno intoleranco za galaktozo, odsotnostjo encima laktaze ali malabsorpcije glukoze/galaktoze ne smejo jemati tega zdravila.
You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel BGR and acetylsalicylic acid for this condition.
Povedati so vam morali, da so "peroralni antikoagulanti" pri tej motnji učinkovitejši kot acetilsalicilna kislina ali kombinirana uporaba zdravila Clopidogrel BGR in acetilsalicilne kisline.
After first opening of the bottle, the medicinal product should be used within 2 months.
Po prvem odprtju vsebnika je zdravilo uporabno še 2 meseca.
Boxes of 30 and 500 film-coated tablets in bottles are available.
Na voljo so škatle po 30 in 500 filmsko obloženih tablet v vsebnikih.
Then, the recommended dose is one 75 mg tablet of Clopidogrel BGR per day as described above.
Priporočeni odmerek je ena 75-mg tableta zdravila Clopidogrel BGR na dan, kot je opisano zgoraj.
What Clopidogrel BGR looks like and contents of the pack The film-coated tablets are pink, round and slightly convex.
Izgled zdravila Clopidogrel BGR in vsebina pakiranja Filmsko obložente tablete so rožnate, okrogle in rahlo izbočene.
Your doctor should have prescribed Clopidogrel BGR plus acetylsalicylic acid if you cannot take ‘oral anticoagulants' and you do not have a risk of major bleeding.
Zdravnik naj bi vam predpisal zdravilo Clopidogrel BGR skupaj z acetilsalicilno kislino, če ne morete prejemati "peroralnih antikoagulantov", ali če nimate tveganja za večjo krvavitev.
If you take more Clopidogrel BGR than you should Contact your doctor or the nearest hospital emergency department because of the increased risk of bleeding.
Če ste vzeli večji odmerek zdravila Clopidogrel BGR, kot bi smeli Zaradi povečanega tveganja za krvavitev se posvetujte s svojim zdravnikom ali z medicinskim osebjem na najbližjem bolnišničnem oddelku za nujno zdravniško pomoč.
Boxes of 7, 14, 28, 30, 50, 56, 60, 84, 90 and 100 film-coated tablets in blisters are available.
Na voljo so škatle po 7, 14, 28, 30, 50, 56, 60, 84, 90 in 100 filmsko obloženih tablet v pretisnih omotih.
If you become pregnant while taking Clopidogrel BGR, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
Če med zdravljenjem z zdravilom Clopidogrel BGR zanosite, se takoj posvetujte s svojim zdravnikom, saj jemanje klopidogrela med nosečnostjo ni priporočljivo.
Driving and using machines Clopidogrel BGR is unlikely to affect your ability to drive or to use machines.
Vpliv na sposobnost upravljanja vozil in strojev Ni verjetno, da bi zdravilo Clopidogrel BGR vplivalo na vašo sposobnost za vožnjo ali upravljanje strojev.
• Paediatric population Clopidogrel should not be used in children because of efficacy concerns (see section 5.1).
- Pediatrična populacija Klopidogrel naj se pri otrocih ne uporablja iz razlogov, ki zadevajo učinkovitost (glejte poglavje
If you think any of these apply to you, or if you are in any doubt at all, consult your doctor before taking Clopidogrel BGR.
Če menite, da se karkoli od navedenega nanaša na vas, ali če ste kakorkoli v dvomih, se posvetujte s svojim zdravnikom, preden vzamete zdravilo Clopidogrel BGR.
If you have experienced severe chest pain (unstable angina or heart attack), you may be prescribed Clopidogrel BGR in combination with acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever.
Če ste doživeli hudo bolečino v prsih (nestabilna angina pektoris ali srčni napad), so vam morda predpisali zdravilo Clopidogrel BGR v kombinaciji z acetilsalicilno kislino, učinkovino, ki je prisotna v številnih zdravilih za lajšanje bolečine in zniževanje zvišane telesne temperature.
What Clopidogrel BGR is and what it is used for
Kaj je zdravilo Clopidogrel BGR in za kaj ga uporabljamo
Blister of OPA/Alu/PVC-Alu containing 7, 14, 28, 30, 50, 56, 60, 84, 90 and 100 film-coated tablets in the box.
Pretisni omoti (OPA/Al/PVC-Al): 7, 14, 28, 30, 50, 56, 60, 84, 90 in 100 filmsko obloženih tablet, v škatli.
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel BGR.
Če ste noseči ali mislite, da ste noseči, morate o tem obvestiti svojega zdravnika ali farmacevta, preden vzamete zdravilo Clopidogrel BGR.
- The other ingredients are lactose (see section 2 ‘Clopidogrel BGR contains lactose'), microcrystalline cellulose, pregelatinised maize starch, macrogol 6000 and hydrogenated castor oil in the tablet core and hypromellose (E464), titanium dioxide (E171), red iron oxide (E172), talc and propylene glycol in the film-coating.
- Druge sestavine zdravila so laktoza (glejte poglavje 2 "Zdravilo Clopidogrel BGR vsebuje laktozo"), mikrokristalna celuloza, predgelirani koruzni škob, makrogol 6000 in hidrogenirano ricinusovo olje v jedru tablete ter hipromeloza (E464), titanov dioksid (E171), rdeči železov oksid (E172), smukec in propilenglikol v filmski oblogi.
The recommended dose, including for patients with a condition called ‘atrial fibrillation' (an irregular heartbeat), is one 75 mg tablet of Clopidogrel BGR per day to be taken orally with or without food, and at the same time each day.
Priporočeni odmerek, vključno za bolnike, ki imajo bolezensko stanje, imenovano "atrijska fibrilacija" (nepravilen srčni utrip), je ena 75-mg tableta zdravila Clopidogrel BGR na dan, ki jo lahko vzamete s hrano ali brez nje; odmerek morate jemati vsak dan ob istem času.
7 film-coated tablets: EU/1/09/558/001 14 film-coated tablets: EU/1/09/558/002 28 film-coated tablets: EU/1/09/558/003 30 film-coated tablets: EU/1/09/558/004 50 film-coated tablets: EU/1/09/558/005 56 film-coated tablets: EU/1/09/558/006 60 film-coated tablets: EU/1/09/558/007 84 film-coated tablets: EU/1/09/558/008 90 film-coated tablets: EU/1/09/558/009 100 film-coated tablets: EU/1/09/558/010
7 filmsko obloženih tablet: EU/1/09/558/001 14 filmsko obloženih tablet: EU/1/09/558/002 28 filmsko obloženih tablet: EU/1/09/558/003 30 filmsko obloženih tablet: EU/1/09/558/004 50 filmsko obloženih tablet: EU/1/09/558/005 56 filmsko obloženih tablet: EU/1/09/558/006 60 filmsko obloženih tablet: EU/1/09/558/007 84 filmsko obloženih tablet: EU/1/09/558/008 90 filmsko obloženih tablet: EU/1/09/558/009 100 filmsko obloženih tablet: EU/1/09/558/010
You have been prescribed Clopidogrel BGR to help prevent blood clots and reduce the risk of these severe events because: - You have a condition of hardening of arteries (also known as atherosclerosis), and - You have previously experienced a heart attack, stroke or have a condition known as peripheral arterial disease.
Zdravilo Clopidogrel BGR vam je predpisano za pomoč pri preprečevanju nastajanja krvnih strdkov in za zmanjšanje tveganja teh hudih dogodkov, ker: - imate otrdele arterije (znano tudi kot ateroskleroza) in - ste predhodno doživeli srčni napad, kap ali imeli stanje, ki je znano kot periferna arterijska bolezen, ali - ste doživeli hudo obliko bolečine v prsih (nestabilna angina ali srčni napad).